Drug Profile
HMPL 004
Alternative Names: HMPL-004Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer HUTCHMED; Nutrition Science Partners
- Class Anti-inflammatories; Antiulcers
- Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Crohn's disease
- No development reported Ulcerative colitis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Crohn's-disease(In volunteers) in Australia (PO)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in Australia (PO)
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED